anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obstructive sleep apnea is a common sleep-breathing disorder characterized by repetitive complete cessation of breathing due to pharyngeal obstruction. Untreated, it has been strongly associated with daytime sleepiness, hypertension, depression, coronary artery disease, stroke, and even death. It is estimated that up to 25% of men and 9% of women may suffer from this condition. One proposed mechanism of pharyngeal obstruction is that the posterior tongue is susceptible to collapse when supine during sleep, which causes further collapse of the soft palate and related structures. Treatment includes continuous positive airway pressure (CPAP), mandibular advancement devices, and various surgical options. There are many surgical options for treating tongue base collapse, many of which are morbid with significant pain and discomfort involved. Silhouette Sutures (Kolster Methods, Inc.) are designed to hold and grip soft tissues using intermittently placed dissolvable cones spaced by knots. It has been used widely for years for facial cosmetic procedures with excellent results and safety record. This is a pilot study evaluating the practicality and efficacy of using Silhouette Sutures in an innovative, minimally invasive technique that obviates the need for more aggressive and morbid procedures for obstructive sleep apnea.
Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
The present invention relates to a compound or the pharmaceutically acceptable salt thereof that has an excellent DGAT inhibiting action and the antifeeding activity. The compound of the following formula(I): [wherein, R1 represents a phenylaminocarbonyl group which may be independently substituted with 1 to 5 substituents selected from substituent group A, a benzoxazol-2-yl group which may be independently substituted with 1 to 3 substituents selected from substituent group A, and etc.; R2 independently represents a C1-6 alkyl group; R3 represents a group of the formula -C(=O)-O-R4; R4 represents a hydrogen atom, a C1-6 alkyl group which may be independently substituted with 1 to 3 substituents selected from substituent group B, and etc.; X represents an oxygen atom, a methylene group or a group of the formula -NH-, etc.; L represents a single bond, a methylene group etc.; ...... represents a single bond or a double bond; m represents an integer of 1 or 2; n represents an integer of 0 to 5, the substituent group A represents a halogen atom, a C1-6 alkyl group, a C1-6 nalo alkyl group, a C1-6 alkoxyl group etc.; the substituent group B represents a C3-6 cycloalkyl group, a phenyl group, a carboxyl group etc.]; or the pharmaceutically acceptable salt thereof.
Cannabis use is particularly prevalent and problematic among youth. Compared with only one in eleven cannabis-exposed adults, one in six cannabis-exposed youth develops cannabis use disorder. Moreover, youth are more prone than adults to potentially lasting adverse effects of cannabis use, including cognitive impairment, altered brain development, poor educational outcome, and diminished life achievement. Despite this, relatively little work has focused on developing optimally efficacious cannabis use disorder treatments, particularly among youth. Current evidence-based treatments convey generally small to modest effect sizes, and novel approaches are critically needed. Among the most promising approaches is the over-the-counter antioxidant medication N-acetylcysteine (NAC). Our team previously demonstrated superior NAC versus placebo (PBO) abstinence outcomes in youth with CUD who concurrently received the behavioral treatment contingency management (CM). Further work is now needed to test whether NAC is efficacious without a platform of CM. The proposed trial is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO, yielding two equally-allocated treatment groups. All participants will receive brief weekly cannabis cessation counseling and medication management. The primary efficacy outcome will be the proportion of negative urine cannabinoid tests during the 12-week active treatment, compared between groups. We will also serially assess cognitive task performance, examining changes in performance among participants who achieve abstinence versus those that do not. This proposed trial is the clear "next step" in the assessment of NAC as an extremely promising youth CUD treatment modality, and is positioned to inform researchers, clinicians, and the general public, addressing a critical need for optimization of youth CUD treatment.
PURPOSE:To provide an antidepressant containing a cyclohexane derivative as an active component, having antidepressing action, useful for the remedy of depression of mammal (human, horse, dog, etc.) and applicable by oral or parenteral administration. CONSTITUTION:A cyclohexane derivative of formula I (R is alkyl; R<1> and R<2> are H or organic residue) is used as an active component of the objective antidepressant. It can be administered orally or parenterally. In the case of oral administration, the cyclohexane derivative is properly mixed with a pharmacologically allowable additive (e.g. carrier, excipient or diluent) and used in the form of powder, tablet, capsule, troche, solution, etc. In the case of parenteral administration, the compound is used as intravenous or intramuscular injection, suppository, etc., in the form of an aqueous solution or nonaqueous suspension. The daily dose of the active component is preferably about 0.01-1mg for adult. The compound of formula I is e.g. the compound of formula II.
Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
PURPOSE: To shorten the time to be required for the reception of medicines by transmitting information described in a prescription to a pharmacy previously selected by a person who has made reservation for it. CONSTITUTION: A reader 5a, a facsimile (FAX) equipment 5b and a copying device 5c are arranged on the center of the inside of a device body 9 and plural sheets of information presenting paper 17 are laminated under the devices 5a to 5c. Prescription information described in a prescription 20 inserted from a prescription inserting port 18 formed on the upper part of the front face of the body 9 and supplied through a 1st carrier 19 is read out. A required pharmacy is selected by a pharmacy selecting means on pharmacy information stored in a storage means. The FAX equipment 5b transmits the read information to the selected pharmacy as FAX information. The copying device 5c prints out pharmacy information on the surface of information presentation paper 17. The prescription 20 and the paper 17 are discharged from a receiving port 22 formed under the inserting port 18.
This cohort includes the analysis of a multicentric retrospective cohort of more than 2,000 patients. This cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model). All available clinical data will be collected. Also, CT and PET scans will be collected and a first radiomic signature.
Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
Hyponatremia can occur as a result of treatment with CARNEXIV. In many cases, the hyponatremia appears to be caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment appears to be dose-related. Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. Signs and symptoms of hyponatremia include headache, new or increased seizure frequency, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Consider discontinuing CARNEXIV in patients with symptomatic hyponatremia.
In the preoperative period, the participants will be taken to the block room. The participants will be monitored, standard sedation will be applied.

The first group will be get interscalene block. The second group will be get suprascapular and axillary block. The third group patient will be get no block. Afterwards, the participants will be operated under general anesthesia. A patient-controlled analgesia device will be attached to each group of participants and their postoperative follow-up will be made.
BACKGROUND: Chronic constipation (CC) is one of the most frequently reported gastrointestinal disorders in the general population and a prominent problem among university students. The study aimed to evaluate the prevalence and the associated factors of CC among Japanese university students.
METHODS: This cross-sectional study was conducted among university students at Hiroshima University, Japan. Students answered the web questionnaire when making a web reservation for the health checkup (April 1 to May 31, 2023). The web questionnaire consisted of four sections, including baseline characteristics, lifestyle factors, family history of CC, and three scales to assess depression and eating disorders: the Beck Depression Inventory (BDI), Eating Attitudes Test (EAT)-26 and Bulimic Investigatory Test (BITE). CC was diagnosed using Rome IV criteria. The multivariate logistic regression model was used to determine CC-related factors.
RESULTS: Out of 10,500 individuals who participated in the annual health checkup, 7,496 participants answered the web questionnaire, of whom 5,386 answered all the survey questions. The mean age of the students was 21.1 ± 4.1 years. The male-to-female ratio was 1:1.17. The prevalence of CC was 13.7%. Factors significantly associated with CC in the multivariate model were first-degree family members with CC [Odd ratio (OR): 2.77, 95% confidence interval (CI): 2.31-3.31], severe depression according to BDI scale (OR: 2.59, 95% CI: 1.96-3.43), female sex (OR: 2.00, 95% CI: 1.69-2.36), and short sleep duration of 6 hours or less per day (OR: 1.28, 95% CI: 1.09-1.50). Lack of physical exercise tended to be associated with CC (OR: 1.19, 95% CI: 1.00-1.40).
CONCLUSIONS: CC is prevalent among Japanese university students. Significant risk factors for CC included the first-degree family history of CC, severe depression, female sex, and short sleep duration. Lack of physical exercise tended to be associated with CC. This may contribute to implementing suitable education health programs, health care professionals, and public health policies to identify individuals at risk for CC to prevent and treat CC effectively.
The present invention discloses a pure Chinese medicine radix angelicae coumarin blood activating and stasis dissolving paste. Radix angelicae coumarin is obtained by the method of extracting the radix angelicae with ethanol heating reflux, filtering, concentrating, metering the volume with water after the alcohol precipitation of the concentrated solution, extracting by petroleum ether, extracting by chloroform, recycling the chloroform, concentrating and drying. The coumarin extraction method of the present invention is simple in operation and quick. Ethanol is used as the solvent, and is low in price and poisonless. The chloroform after extraction can be removed by a simple method. The content of the coumarin extracted by the method is up to 50% or more. The repeatability is good. The solvent can be reused. Applying the radix angelicae coumarin extracted by the present invention to the blood activating and stasis dissolving paste, the aim is to solve the problem that the medicine for the treatment of cervical spondylosis, lumbar disc herniation, and bone hyperplasia is large in side effects and uncertain in efficacy. The blood activating and stasis dissolving paste has the following advantages that: raw materials of the medicine are mainly natural herbs, the combined effect of the Chinese herbs is used for the treatment of cervical spondylosis, lumbar disc herniation, and bone hyperplasia, the medicine is nontoxic to humans, each component in the medicine complies with the regulation of the pharmaceutical affairs, and the medicine is easy to use, tasteless, and definite in efficacy.
An apparatus and method of operation is provided for a contrast media injector having a powered drive ram. The drive ram is designed to interface with a plunger of a syringe in order to move the plunger forward and backward relative to a barrel of the syringe. The syringe, having an RF data tag associated therewith, is mounted on to the contrast media injector. Electromagnetic signals are transmitted from an electromagnetic device of the injector in response to mounting the syringe. Data is electromagnetically read from the RF data tag of the syringe using the electromagnetic device of the injector. The transmitting is terminated after the electromagnetically reading. Medical fluid is then dispensed from the syringe. Electromagnetic signals are transmitted from the electromagnetic device in response to initiation of the dispensing. Data is electromagnetically written to the RF data tag of the syringe using the electromagnetic device of the injector.
Disclosed are methods that achieve i) site-directed delivery, ii) in situ amplification, and iii) sustained expression of an exogenous gene product within renal glomeruli. An exogenous gene, E. coli  beta -galactosidase, was introduced into cultured rat mesangial cells using a replication-defective retrovirus, and stable infectants were administered to a rat kidney via the renal artery. In the injected kidney, the engineered, cultured mesangial cells populated 40% of glomeruli site-specifically. The gene product was detected throughout a 14-week period of observation. In an alternative method, engineered, cultured mesangial cells were injected into a kidney subjected to an antibody that induces mesangiolysis followed by mesangial regeneration. Under these conditions, expression of  beta -galactosidase was dramatically amplified in situ, and high level expression continued for at least 8 weeks.
PURPOSE:An improver for lipometabolism useful for arterosclerosis, hyperlipemia, etc., having low toxicity, reducing blood triglyceride, cholesterol, etc., containing a halogen-substituted phenylhydantoin or its salt as an active ingredient. CONSTITUTION:A compound shown by the formula (X1 and X2 are H, F, Cl, or Br, with the proviso that the case where both are H is omitted) or its salt is used as an improver for lipometabolism. 5-(4-Fluorophenyl)-5-phenylhydantoin may be cited as the example. The compound shown by the formula has improved reducing action on blood cholesterol, free fatty acid, and beta-lipoprotein, and increasing action on blood high-density lipoprotein, and is found to be useful as an improver for lipometabolism. It is effective for remedying and preventing arteriosclerosis, hyperlipemia, diseases of circulatory organs. A dose is usually 50-1,200mg/day.
The interventional group received stretching and strengthening exercises along with scapular clock exercises. For the first two weeks, only scapular clock exercises were performed by the patient actively. After 2 weeks, the subjects performed scapular clock exercises by using the thera-band.
Patients for total hip replacement will be randomized for surgical anesthesia with either lumbosacral plexus blockade or continuous spinal anesthesia. All patients will receive central venous, arterial and spinal catheters. Hemodynamics will be monitored with transpulmonary thermodilution and pulse contour analysis. Perineural injection of study medicine around the lumbar and sacral plexus will be performed guided by ultrasound and nerve stimulation. Study medicine will be injected in divided doses in the spinal catheter. Treatment will be blinded using double-dummy technique. After the first intrathecal dose of study medicine, the hemodynamic response will be monitored for 60 minutes. Patients will then be transferred to the operating room, where total hip replacement will be performed in lumbosacral plexus blockade or spinal anesthesia according to randomization.
PBC patients with poor ursodeoxycholic acid (UDCA) response are selected and randomly assigned into probiotic group and control group. Patients in probiotic group receive probiotic(Micro V Probiotics) combined UDCA for 6 months and then continue to take UDCA alone. Patients in control group continue to take UDCA alone. Biochemical indicators, immunological indicators, liver stiffness, and ultrasound of the two groups of patients were collected. GLOBE and UK-PBC scoring system are used to assesse prognosis.The feces and serum of all patients are collected to observe the differences in fecal microbial polymorphisms in the two groups of patients. Metabolomics are used to study the differences in the bile acids and short chain fatty acid metabolites of the serum and feces of the two groups of PBC patients.
A system and method for multi-modality fusion for 3D printing of a patient-specific organ model is disclosed. A plurality of medical images of a target organ of a patient from different medical imaging modalities are fused. A holistic mesh model of the target organ is generated by segmenting the target organ in the fused medical images from the different medical imaging modalities. One or more spatially varying physiological parameter is estimated from the fused medical images and the estimated one or more spatially varying physiological parameter is mapped to the holistic mesh model of the target organ. The holistic mesh model of the target organ is 3D printed including a representation of the estimated one or more spatially varying physiological parameter mapped to the holistic mesh model. The estimated one or more spatially varying physiological parameter can be represented in the 3D printed model using a spatially material property (e.g., stiffness), spatially varying material colors, and/or spatially varying material texture.
Porcine reproductive and respiratory syndrome (PRRS) is one of the costliest diseases to pork producers worldwide. We tested samples from the pregnant gilt model (PGM) to better understand the fetal response to in-utero PRRS virus (PRRSV) infection. Our goal was to identify critical tissues and genes associated with fetal resilience or susceptibility. Pregnant gilts (N=22) were infected with PRRSV on day 86 of gestation. At 21 days post maternal infection, the gilts and fetuses were euthanized, and fetal tissues collected. Fetuses were characterized for PRRS viral load in fetal serum and thymus, and preservation status (viable or meconium stained: VIA or MEC). Fetuses (N=10 per group) were compared: uninfected (UNIF; <1 log/µL PRRSV RNA), resilient (HV_VIA, >5 log virus/µL but viable), and susceptible (HV_MEC, >5 log virus/µL with MEC). Gene expression in fetal heart, kidney, and liver was investigated using NanoString transcriptomics. Gene categories investigated were hypothesized to be involved in fetal response to PRRSV infection: renin- angiotensin-aldosterone, inflammatory, transporter and metabolic systems. Following PRRSV infection, CCL5 increased expression in heart and kidney, and ACE2 decreased expression in kidney, each associated with fetal PRRS susceptibility. Liver revealed the most significant differential gene expression: CXCL10 decreased and IL10 increased indicative of immune suppression. Increased liver gene expression indicated potential associations with fetal PRRS susceptibility on several systems including blood pressure regulation (AGTR1), energy metabolism (SLC16A1 and SLC16A7), tissue specific responses (KL) and growth modulation (TGFB1). Overall, analyses of non-lymphoid tissues provided clues to mechanisms of fetal compromise following maternal PRRSV infection.
Addressing the epidemic of obesity is a national priority. Currently almost a third of children and two thirds of adults are overweight or obese. Obesity-related chronic health problems originating in childhood are often life-long. Overweight and obesity result from detrimental patterns of dietary intake and physical activity. These obesity-producing lifestyles are established in childhood and are often carried into adulthood, when they become more refractory to change. Research has demonstrated that programs involving parents and children in a family context have been the most effective in preventing and treating childhood obesity.

Research Question 1: How many parents and children agree to participate, complete data collection and complete at least 80% of the intervention? Research Question 2: What reasons are given by those not completing the protocol and what suggestions are offered by those who do complete the protocol? Research Question 3: What is the relationship of parent or child perceptions of authoritative parenting, child perceptions of family models and support for healthy eating, physical activity, or reduced sedentary time, and of parenting stress, self-efficacy, confidence, and eating behavior on child BMI? Research Question 4: Do parent or child perceptions of authoritative parenting, diet, physical activity, fitness or body composition; child perceptions of family models and support for healthy eating, physical activity, or reduced sedentary time; or parent perceptions of parenting stress, self-efficacy, confidence, and eating behavior change across the study time period? Research Question 5: Are there relationships between study completion and child or parent BMI, child or parent gender, parenting stress, self-efficacy, confidence, and eating behavior?
PROBLEM TO BE SOLVED: To obtain a protein specifically inhibiting antagonistically the binding of chemokine TECK to CCR9 receptor, to obtain a DNA encoding the protein, to provide a method for screening the protein, and to obtain a prophylactic or therapeutic agent for diseases in which the chmokine TECK or CCR9 receptor is involved. SOLUTION: The protein is composed of an amino acid sequence represented by the sequence No.1 (refer to the specification). Or is composed of an amino acid sequence wherein at least one amino acid is substituted for, deleted from or added to the above amino acid sequence and functions to specifically inhibiting antagonistically the binding of chemokine TECK to CCR9 receptor. The DNA encodes the above proteins. Further, a method for screening a substance specifically inhibiting the binding of chemokine TECK to CCR9 receptor is characterized by using the above protein(s) as marker ligand(s). Besides, a pharmaceutical composition having the above protein(s) or the substance obtained by the above screening method as the active ingredient is provided.